CAROLINE CATE: Open Payments
NPI 1649924846 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$292 in 15 payments from 10 companies in 2025. Trend: 2023 $360 · 2024 $347 · 2025 $292
Food & beverage: $292
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $48 |
| Corcept Therapeutics | 2 | $47 |
| PFIZER INC. | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Indivior Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: Korlym, ELIQUIS, XIFAXAN, GVOKE HYPOPEN, SUBLOCADE, Rybelsus, Wegovy, REXULTI.
Industry payments across AL — which companies pay providers there.
